葵花药业(002737) - 2025 Q2 - 季度业绩预告

Part I I. 2025 Semi-Annual Performance Forecast The company forecasts a substantial year-over-year decline in its 2025 first-half performance, with net profit attributable to shareholders, non-recurring net profit, and basic EPS all significantly decreasing 2025 Semi-Annual Performance Forecast | Item | Current Period (Estimated) (million yuan) | Prior Year Same Period (million yuan) | Year-over-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 70 - 85 | 486.3328 | Decrease 82.52 - 85.61 | | Net Profit Excluding Non-Recurring Items | 40 - 55 | 459.7065 | Decrease 88.04 - 91.30 | | Basic Earnings Per Share (yuan/share) | 0.12 - 0.15 | 0.83 | - | III. Explanation of Performance Changes Performance decline is primarily due to proactive shipment controls for channel inventory reduction and increased operating costs from high-priced raw materials and reduced production scale - The company proactively streamlined downstream channels by controlling total shipments to reduce inventory across the supply chain, directly impacting first-half performance but benefiting long-term healthy development[6] - Following nearly a year of channel optimization, the company's product channel inventory has gradually normalized, with second-quarter operating revenue stabilizing and steadily recovering compared to the first quarter[6] - High raw material inventory costs, combined with increased fixed cost allocation due to reduced production scale, collectively drove up operating costs, significantly impacting product sales gross margin[6] II, IV, V. Other Explanations and Risk Warnings The company states this performance forecast is a preliminary, unaudited estimate, with final data subject to the official semi-annual report, and confirms no significant uncertainties - This performance forecast represents preliminary estimates by the company's finance department and has not been audited by an accounting firm[4] - The company confirms there are no significant uncertainties currently known that could affect the accuracy of this performance forecast[7] - The final specific financial data will be based on the company's officially disclosed 2025 semi-annual report, and investors are advised to be aware of investment risks[8]